Total Credits:
1.0
including
1.0 AOA Category 1-A Credit(s)
- Average Rating:
-
Not yet rated
- Faculty:
-
William Elliott, M.D. Ph.D.
- Short Description:
- First presented as part of the annual convention in June 2024, WOMA is pleased to offer this presentation as an on-demand CME seminar.
Learning Objectives:
1. List the glucagon-like peptide (GLP)-1 agonists available in the USA, and compare and contrast them with regards to:
a. Mechanism of action and molecular pharmacology
b. Indications and contraindications
c. Adverse effects and cost
2. Summarize the results of cardiovascular outcome trials with GLP-1 agonists with respect to:
a. Major adverse cardiovascular events (3- vs. 4-component outcomes)
b. Renal function in diabetic subjects
c. Weight loss
3. Cite the results of randomized clinical trials with GLP-1 agonists performed in obese/overweight subjects with the primary outcome of weight loss, and explain why the statistical method for assessing differences may be biased.
4. Name at least 4 adverse effects of GLP-1 agonists, and how each can be mitigated when prescribed in daily clinical practice.
- Price:
-
$45.00
- Base Price
